Investor Presentation • Feb 10, 2022
Investor Presentation
Open in ViewerOpens in native device viewer
Interim report Q4 2021
10 February2021
Certain statements made in this Presentation may include forward-looking statements. These statements relate to the Company's expectations, beliefs, intentions or strategies regarding the future. The forward-looking statements reflect the Company's current views and assumptions with respect to future events and are subject to risks and uncertainties.
All though the Company believes that its expectations and the Presentation are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in the Presentation.
Carasent ASA is making no representations or warranty, expressed or implied, as to the accuracy, reliability or completeness of the Presentation, and neither Carasent ASA, nor any of its directors, officers, employees or advisors will have any liability to you or any other person resulting from your use.
DRIVERS
PROBLEM
The need for high-quality healthcare at lower cost to society has never been greater
The healthcare industry is facing underlying structural issues
| webdocx | $\alpha$ Search anything |
$\Box$ Cinic ID $\sim$ | R John A. Zoldberg, N | |||
|---|---|---|---|---|---|---|
| ይ | Search patient ID $\mathbb{Q}$ |
Dashboard » | ||||
| ஃ | + NEW PATIENT | Welcome, dr. Zoidberg! | Appointments Today, 14 may 2021 |
$\equiv$ | ||
| 圄 | Upcoming appointments ü |
You have no unread messages × |
$09.00 - 10.00$ Name Surname Session #2 |
|||
| Name Surname Patient ID | 3 unsigned entries Patient ID view-mm-dd |
B $\bullet$ |
11:00 - 12:00 Name Surname A |
|||
| 扄 | Name Surname Patient ID Name Surname Patient ID |
Patient ID vann-mm-dd | B $\bullet$ |
Session #2 $13.00 - 14.00$ |
||
| $\Box$ | Name Surname Patient ID | Patient ID vyw-mm-dd $\circ$ |
B $\bullet$ |
Name Surname Session #2 |
||
| 3 Recently viewed v |
Other tasks | 14:00 - 15:00 Name Surname |
||||
| ⊙ | Name Sumame Patient ID Name Surname Patient ID |
Wash car Water office plant |
⊗ × $\circ$ $\times$ |
Session #2 | ||
| Name Surname Patient ID | New task | $\mathcal{C}$ | 15:00 - 16:00 Name Surname Session #2 |
|||
| $\circledR$ | Name Surname Patient ID | |||||
| webdocx | Search anything | $\mathbb{Q}$ | $\Box$ case o $\sim$ | John A. Zoidberg, MD . | |
|---|---|---|---|---|---|
| $\times$ 8 Jane Doe 83-11-28 $\mathbf{D}$ 37 years old 9 |
Pottent list > Jane Doe & Jane doe D MESSAGE |
||||
| ஃ 京 Patient overview |
Personal info | ĭ | RISK OF HARMING SELF | RISK OF HARMING OTHERS | |
| 启 Journal |
GENERA PHONE MUNEER 123 - 456 78 910 Female |
PHYSICAL ADRESS 123 Street name |
|||
| Д 旧 Labs |
EWAIL ADRESS DATE OF BIRTH 1234-56-78 [email protected] |
Hometown 123 45 United kingdom |
High | Moderate | |
| 曲 | |||||
| Diagnoses NAME |
CODE DIASNOSED |
NEDICATION | $\ddot{\phantom{0}}$ TREATMENT |
||
| $\Box$ | Attention-deficit hyperactivity disorder predominantly inattentive type |
F90.8 2018-11-21 |
Ritalin 10 mg Concerta 36 mg |
Group CBT PAP |
|
| 6 | Timeline | ||||
| (2) | Evaluation Session 2 Missed 20 may 2020 20 may 2021 20 may 2021 $\Box$ $\Box$ $\Box$ |
Session 3 20 may 2021 $\Box$ |
Self report form 20 may 2021 H |
Session 3 20 may 2021 - - -> $\Box$ |
| Ramping up investments for Webdoc X, our new offering for the European market |
|---|
| UK as the first target market |
| Ongoing pilot project Mindler is progressing according to plan |
Plan to launch the product commercially in 2023
Clear expansion opportunities across geographic presence and healthcare verticals
Proven track record and capabilities
Carasent leading the consolidation
Established model for creating and extracting synergies
Revenue guidance 2021 – Avans Soma & Evimeria EBITDA guidance 2021 – Avans Soma & Evimeria
Outlook
18
Geographic expansion
| 3 Months Ended December 31, 2021 |
||||||||
|---|---|---|---|---|---|---|---|---|
| in NOK |
Evimeria | Avans Soma |
Metodika | Carasent AS |
Carasent | Carasent | Q4-21 | |
| (Amounts 1,000) |
Recurring | Non-recurring (* |
||||||
| Active clinics/units |
619 | 171 | 54 | 844 | ||||
| Operating Total Revenues |
23,374 | 9,240 | 7,363 | - | - | 39,977 | ||
| Total Cost of Sales |
4,795 | 1,470 | 1,095 | - | - | 7,360 | ||
| Gross Profit |
18,579 | 7,770 | 6,269 | - | - | - | 32,617 | |
| Operating Expenses |
||||||||
| Employee Compensation and Benefits |
6,795 | 3,154 | 4,407 | - | 1,079 | 15,436 | ||
| Other Operational and Administrative Costs |
2,533 | 2,248 | 964 | 240 | 722 | 7,967 | 14,674 | |
| Operating Total Expenses |
9,328 | 5,403 | 5,371 | 240 | 1,802 | 7,967 | 30,110 | |
| EBITDA | 9,251 | 2,367 | 898 | (240) | (1,802) | (7,967) | 2,507 | |
| Cash D&A |
903 | 168 | 1,071 | |||||
| Non Cash D&A |
1,719 | 1,609 | 561 | - | 804 | - | 4,693 | |
| Depreciation and Amortization |
2,622 | 1,777 | 561 | - | 804 | 5,764 | ||
| EBIT | 6,630 | 590 | 337 | (240) | (2,606) | (7,967) | (3,257) | |
| Total Other Expense |
(101) | 3 | (67) | (116) | 13,886 | 13,605 | ||
| (loss) Before Income Income Taxes |
6,529 | 593 | 270 | (356) | 11,280 | (7,967) | 10,349 | |
| Income Tax Expense |
(550) | (77) | 66 | - | - | (560) | ||
| Net Income (loss) for the Period |
5,978 | 517 | 336 | (356) | 11,280 | (7,967) | 9,788 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.